Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Liphorus Pharmaceuticals Logo
Liphorus Pharmaceuticals CB Rank
640058
Heat Score
8
Liphorus Pharmaceuticals develops therapeutic antibodies that can be used to treat hypercholesterolemia.
Founded
obfuscation
PrivateSeries A Montréal, Quebec, Canada1-10 www.liphorus.com/
Pharmaceutical
Overview

Liphorus Pharmaceuticals
Total Funding
obfuscation
Heat Score
8

Total Funding
obfuscation
obfuscation
Series A raised
obfuscation
Growth Score
pts
in past quarter
Heat Score 8
-21 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Liphorus Pharmaceuticals

CB Rank
640058
Liphorus Pharmaceuticals develops therapeutic antibodies that can be used to treat hypercholesterolemia.
Founded
obfuscation
PrivateSeries A Montréal, Quebec, Canada1-10 www.liphorus.com/
Pharmaceutical

Funding Rounds

Series A
OBF
in
obfuscation

Key People

Details

Legal Name Liphorus Pharmaceuticals Inc.
Operating Status Active
Company Type For Profit
Founders  Andrew Jennings, Nabil Seidah
About the Company
Liphorus Pharmaceuticals develops small compounds that target PCSK9 to treat hypercholesterolemia. Along with this initial round of funding, the company has a research agreement with the IRCM that will enable it to create and validate compounds that target PCSK9.
Contact Email info@liphorus.com
Predictions & Insights

Products & Services

Therapeutic Antibodies Targeting PCSK9
Antibodies developed to inhibit PCSK9, reducing LDL cholesterol levels by preventing PCSK9-induced degradation of LDL receptors.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A
obfuscation
Series A - Liphorus Pharmaceuticals Logo
Series A - Liphorus Pharmaceuticals
2
obfuscation
Sanderling Ventures, UnivalorSeries A

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 2

Employee Profiles

News
Technology
View Tech Report
Sub-Organizations
Frequently Asked Questions

Where is Liphorus Pharmaceuticals's headquarters? Liphorus Pharmaceuticals is located in Montréal, Quebec, Canada.Who invested in Liphorus Pharmaceuticals? Liphorus Pharmaceuticals has 2 investors including Sanderling Ventures and  Univalor.When was the last funding round for Liphorus Pharmaceuticals? Liphorus Pharmaceuticals closed its last funding round on
obfuscation
from a Series A round.Who are Liphorus Pharmaceuticals's competitors? Alternatives and possible competitors to Liphorus Pharmaceuticals may include Eli Lilly, Sanofi, and  Pfizer.How much funding has Liphorus Pharmaceuticals raised to date? Liphorus Pharmaceuticals has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(6852caf 1)
|